About Us
Overview
Corporate Governance
Board of Directors
Board Committees
Management
Careers
Technology
DNA Technology
Poloxamer Delivery System
Vaxfectin
®
Adjuvant
Products
Pipeline
VCL-HB01 Therapeutic HSV-2 Vaccine
VL-2397 Antifungal
Other Products
Apex
®
-IHN
Dengue Vaccine
ONCEPT
®
Clinical Trials
Overview & Active Programs
Compassionate Use
Investors
Overview
Stock Information
News Releases
Events & Presentations
SEC Filings
Contact Us
Contact Info
Directions to Vical
Careers
NASDAQ | VICL
:
1.51
+0.04
Products
Pipeline
VCL-HB01 Therapeutic HSV-2 Vaccine
VL-2397 Antifungal
Other Products
Apex
®
-IHN
Dengue Vaccine
ONCEPT
®
Pipeline
VCL-HB01 Therapeutic HSV-2 Vaccine
VL-2397 Antifungal
Apex
®
-IHN
Dengue Vaccine
ONCEPT
®
Other Products
Home
/
Products
/
VCL-HB01 Therapeutic HSV-2 Vaccine
VCL-HB01 Therapeutic HSV-2 Vaccine
Genital Herpes and Herpes Simplex Virus Type-2 (HSV-2)
HSV-2 is a sexually-transmitted virus that is the leading cause of recurrent genital herpes worldwide.
Approximately 16% of the U.S. population and 11% of the worldwide population aged 15 to 49 are infected with HSV-2.
Nearly 20 million new HSV-2 infections occurred worldwide in 2012, with the highest rates among younger age groups.
Most people infected with HSV-2 experience recurrent episodes of painful genital lesions. An infected person may shed virus even when they do not have lesions, which can increase the risk of transmission to an uninfected partner.
There is currently no cure for HSV-2 infection; antiviral drugs can decrease genital lesions, viral shedding and transmission. Despite the availability of antivirals for the past 30 years, HSV-2 prevalence rates remain largely unchanged.
The continuing physical and psychological toll of recurrent genital herpes highlights the need for novel treatment modalities such as therapeutic vaccines.
VCL-HB01: Vical’s Therapeutic HSV-2 Vaccine
Vical’s bivalent DNA vaccine candidate, VCL-HB01, encoding full-length HSV-2 UL-46 and gD antigens, was developed in collaboration with leading HSV-2 experts at the University of Washington.
In a Phase 1/2 randomized, double-blind, placebo-controlled trial of 165 HSV-2 infected adults, VCL-HB01 demonstrated a statistically significant reduction in genital lesion rate compared to baseline.
A Phase 2 randomized, double-blind, placebo-controlled trial in approximately 225 HSV-2 infected adults has been underway since September 2016 to evaluate the primary efficacy endpoint of reduction in annualized recurrence rates over a 12-month follow-up period. Recurrence rate is one of the most clinically meaningful endpoints for patients and treating physicians as it provides information on both the number and spacing of recurrences over time in this chronic disease setting. For more information, please go to the
NCT02837575
trial listing at ClinicalTrials.gov.
References
Corey et al., NEJM 2004
Looker et al., PLOS One, 2015
Mammen et al., ASM Microbe 2016
Muller et al., JGV 2009
WHO Guidelines for the Treatment of Genital Herpes Simplex Virus 2016
Xu et al., MMWR 2010
HSV-2 Vaccine Phase 1/2 Results Presented at ASM Microbe 2016
RELATED LINKS
CDC: Genital Herpes
NIH: Genital Herpes
WebMD: Genital Herpes
Mayo Clinic: Genital Herpes
AAD: Herpes Simplex
Planned Parenthood: Herpes
Women's Health: Genital Herpes
About Us
Overview
Corporate Governance
Board of Directors
Board Committees
Management
Careers
Technology
DNA Technology
Poloxamer Delivery System
Vaxfectin
®
Adjuvant
Products
Pipeline
VCL-HB01 Therapeutic HSV-2 Vaccine
VL-2397 Antifungal
Other Products
Apex
®
-IHN
Dengue Vaccine
ONCEPT
®
Clinical Trials
Overview & Active Programs
Compassionate Use
Investors
Overview
Stock Information
News Releases
Events & Presentations
SEC Filings
Contact Us
Contact Info
Directions to Vical
Careers
CONNECT WITH US
RSS Feeds
Email Alerts
LinkedIn
Slideshare
StockTwits
Twitter
YouTube
© 2017 Vical Inc.
Privacy Policy
Terms of Use
Site Map
P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
Designed by
Mentus
Powered By Q4 Inc.
5.4.1.6
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.